Stiles Financial Services Inc Acquires 89 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Stiles Financial Services Inc boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,432 shares of the biopharmaceutical company’s stock after acquiring an additional 89 shares during the quarter. Regeneron Pharmaceuticals accounts for about 1.3% of Stiles Financial Services Inc’s portfolio, making the stock its 17th largest position. Stiles Financial Services Inc’s holdings in Regeneron Pharmaceuticals were worth $3,606,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Sachetta LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the period. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $26,000. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $28,000. Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $33,000. Finally, Family Firm Inc. bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of a number of recent research reports. Leerink Partners restated a “market perform” rating and set a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Evercore ISI reduced their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $1,092.62.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $827.00 on Friday. The company has a market cap of $91.17 billion, a PE ratio of 20.40, a price-to-earnings-growth ratio of 3.17 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $783.57 and a 52 week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm’s 50-day simple moving average is $1,035.92 and its two-hundred day simple moving average is $1,038.36.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.